Showing 7181-7190 of 7612 results for "".
- Acneiform Eruptions Examined in New Bookhttps://practicaldermatology.com/news/20131223-acneiform_eruptions_examined_in_new_book/2459387/A new book that addresses the differential diagnosis of acne vulgaris and treatment of acne-like condition is now available through Springer. Acneiform Eruptions in Dermatology, edited by Practical Dermatology Board Member Joshua A. Zeichner, MD, offers expert guidance on acne and syst
- Theradome Laser Helmet Launches for At-home Treatment of Hair Losshttps://practicaldermatology.com/news/20131219-theradome_laser_helmet_launches_for_at-home_treatment_of_hair_loss/2459389/Theradome Laser Helmet LH80 PRO, the first FDA and over-the-counter cleared, wearable laser hair restoration treatment, is now available. Developed for in-home use and designed for patients suffering from the effects of thinning hair and Androge
- Valeant Pharmaceuticals to Acquire Solta Medicalhttps://practicaldermatology.com/news/20131216-valeant_pharmaceuticals_to_acquire_solta_medical/2459394/Valeant Pharmaceuticals International, Inc. announced that it has entered into a definitive agreement to acquire all of the outstanding common stock
- Topical Nitric Oxide Shows Promisehttps://practicaldermatology.com/news/20131212-topical_nitric_oxide_shows_promise/2459395/Novan is kicking off a two-year program to support the pharmaceutical development of Nitric Oxide Advanced Healing (NOAH) technology, including formulation work, nonclinical toxicology, and proof of concept studies in models of deep partial-thickness and full-thickness thermal injuries. The
- AAD Issues New Guidelines for Diagnosis and Assessment of Atopic Dermatitishttps://practicaldermatology.com/news/20131204-aad_issues_new_guidelines_for_diagnosis_and_assessment_of_atopic_dermatitis/2459399/The American Academy of Dermatology (AAD) recently announced the release of its new evidence-based guidelines for the diagnosis and assessment of atopic dermatitis based on an extensive review of the scientific literature on this chronic skin condition characterized by itchy, re
- ASLMS Announces Dr. Horace Furumoto Award Recipientshttps://practicaldermatology.com/news/20131126-laser_society_announces_dr_horace_furumoto_award_recipients/2459402/Michael H. Slayton, Ph.D. and Ishan Barman, Ph.D. will receive the Horace Furumoto Innovations Professional Development Awards at the upcoming meeting of the American Society for Laser Medicine & Surgery, Inc. (ASLMS), which will be held in April 2014, in Phoenix, AZ. Dr. Thomas Rohrer, Chair of the
- LEO Pharma Expands QualityCareTM Patient Support Programhttps://practicaldermatology.com/news/20131126-leo_pharma_expands_qualitycaretm_patient_support_program/2459403/LEO Pharma Inc. has expanded its QualityCareTM Program, a free and confidential patient support service for people affected by psoriasis or actinic keratosis. In addition to live nurse support through the www.qualitycarebyleo.com, the website also allows patients to choose relevant topics of interes
- Valeant Pharmaceuticals Announces Appointment of Dr. Ari Kellen to Executive Management Teamhttps://practicaldermatology.com/news/20131125-valeant_pharmaceuticals_announces_appointment_of_dr_ari_kellen_to_executive_management_team/2459405/Valeant Pharmaceuticals International, Inc. announced that Dr. Ari Kellen has been named to Valeant's Executive Management Team and will assume the role of Executive Vice President/Company Group Chairman, effective January 1,
- Investigational Melanoma Agent Improves Survival in Phase III Trialhttps://practicaldermatology.com/news/20131120-investigational_melanoma_agent_improves_survival_in_phase_iii_trial/2459408/Interim results from a pivotal Phase III trial show that Amgen's investigational agent talimogene laherpaepvec increased overall survival in patients with unresected stage IIIB, IIIC, or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). The study found that median ov
- Valeant's Antifungal Agent Luzu Wins FDA Approvalhttps://practicaldermatology.com/news/20131115-valeants_antifungal_luzu_wins_fda_approval/2459414/The FDA has approved Luzu® (luliconazole, Valeant) Cream, 1% for the topical treatment of athlete's foot (interdigital tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis), caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and olde